Introduction __________________________
Systemic lupus erythematosus (SLE) is an autoimmune disease with multi-organ involvement. Arthritis is one of the major clinical findings in SLE reported in up to 90% of patients [1] [2] [3] [4] . Similar to other diseases such as rheumatoid arthritis (RA), arthritis has a considerable effect on disease burden and imperils quality of life [5, 6] . The majority of arthritis lesions in SLE are nonerosive and non-deforming [7, 8] ; however, there is a tendency to develop erosion in RA arthritis [9] . In less than 5% of SLE patients, erosive arthritis develops; this is known as rhupus [10] [11] [12] . Erosive arthritis in SLE has a prognosis and clinical course similar to that of RA [13] . The risk factors for the development of erosive arthritis are not fully understood. Recent studies have challenged the concept of non-erosive arthropathy featured in SLE. In some cases with erosive lesions, it may be difficult to differentiate SLE from RA, and many SLE cases are initially misdiagnosed as having RA [14, 15] . Erosive lesions more strongly debilitate and affect the quality of life in SLE patients [16] . Regarding the difference in particular outcomes, it is helpful to use a serological marker to distinguish them at the onset of disease.
Anti-cyclic citrullinated peptide (anti-CCP) antibodies are highly specific and sensitive measures in RA diagnosis and predict the prognosis of disease [17] . Moreover, in a number of non-RA inflammatory conditions such as SLE, positive Anti-CCP is detectable, which demands careful interpretation [18, 19] . A number of previous studies have proposed an association between anti-CCP and erosive or deforming arthritis in SLE and related complications [20] [21] [22] . However, the association is not adequately addressed in the literature. The current study evaluated the prevalence of anti-CCP various subsets in SLE patients. Patients who fulfilled the American College of Rheumatology (ACR) criteria for SLE were eligible to be enrolled in the current study. The availability of clinical records and radiological exams were other inclusion criteria. Patients with concurrent comorbidities which warranted additional treatment were not eligible to participate in the study.
Materials and Methods _________________
Data regarding recent complete blood count (CBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), anti-dsDNA, fluorescent antinuclear antibody (FANA), complement component 3 (C3), complement component 4 (C4), complement total hemolytic (CH50), anti-cardiolipin (IgG, IgM), creatinine, urine analysis U/A, and urine protein were extracted from the participants' files.
Ten milliliters (ml) of whole blood was collected from each participant, and anti-CCP antibodies were measured using enzyme-linked immunosorbent assays (ELISA) (first generation anti-CCP1-test; Euroimmun, Lübeck, Germany). An anti-CCP level > 5 RU/mL was considered positive. Recent clinical and laboratory findings such as alopecia, leucopenia, photosensitivity, discoid rash, anemia, thrombocytopenia, and raised creatinine (>1 mg/dL) from the patients' files were studied.
Patients with chronic arthritis (more than 6 weeks) had radiography performed on the involved joints to detect the presence of erosive arthritis.
To address the correlation between anti-CCP and arthritis, patients were divided into two groups, those with and those without arthritis. Patient serum levels of anti-CCP and other data were compared in the two subgroups.
Statistical methods
Chi square and Fisher's exact test were applied to compare the two subsets. A p-value less than 0.05 was considered statistically significant. All statistical analyses were carried out with the SPSS software, version 21 (Chicago, IL, USA).
Results _______________________________
The demographic and clinical characteristics of patients with SLE are shown in Table 1 . Positive anti-CCP was detected in 14 out of 300 patients (4.7%, CI: 2.6-7.8). All anti-CCP positive patients were female. In patients with positive anti-CCP, the mean level was 33.96 RU/mL. There was no statistically significant difference in age, gender, or disease duration between the anti-CCP positive and negative subgroups (Table 2) .
Arthritis was present in 170 SLE patients (56.7%). From SLE patients with arthritis, 163 patients (95.9%) had transient arthritis, and 7 (4.1%) had chronic arthritis. Positive anti-CCP was noted in 11 patients with arthritis (6.5%) and 3 patients of the non-arthritis subset (2.3%). The difference in anti-CCP positivity between the two subgroups was not statistically significant (Pvalue= 0.09) ( Table 3 ). Mean anti-CCP titer was 39.35±15.05 RU/mL (mean±S.E) in patients with arthritis and 14.23±4.72 RU/mL (mean±S.E) in those without arthritis (P-value=0.41). Eleven arthritis cases with positive anti-CCP comprised 10 cases of transient arthritis and one of chronic arthritis. The patient with chronic arthritis had erosive joint damage confirmed by x-ray imaging ( Table 3 ). The prevalence rate of anti-CCP positivity among chronic arthritis cases was (14.3%), while 6.1% of transient arthritis cases were anti-CCP positive (Table 3) .
Positive RF was reported in two patients with positive anti-CCP (14.3%). RF-positive cases included one patient with transient arthritis and one with chronic arthritis. There was a significant relationship between anti-CCP and RF in this study (P=0.004).
The anti-CCP-positive subgroup had a higher rate of anti-ds DNA and FANA. However, in comparison with the total studied group, low complement levels were less frequent in anti-CCP-positive cases.
Discussion ____________________________
The concept of non-erosive lupus arthropathy has recently been challenged by innovative radiological techniques. Some studies have postulated that erosive arthritis develops in a higher percentage of SLE patients [23, 24] . However, this debilitating complication has not been amply discussed in the literature. The underlying pathogenesis of erosive arthritis is not fully understood [11] . The predictive value of serological markers in the development of specific lupus complications such as erosive arthritis has been the subject of an ongoing dispute [20] . A review article by Budhram et al. revealed anti-CCP as a predictor of erosive arthritis in SLE [25] . There is growing evidence that suggests a higher prevalence of anti-CCP expression in rhupus in comparison with SLE patients [26] . However, SLE patients with deforming arthropathy demonstrate clinical features comparable to cases of rhupus [27] . Lower levels of complement components (C3, C4, and CH50) were less common among anti-CCP-positive cases in comparison with the whole cohort. This notion may be partly due to the limited number of anti-CCPpositive cases in this study.
The prevalence rate of anti-CCP positivity in sera in this study was similar to that in some previous reports [28, 29] . The prevalence rate of positive anti-CCP and the level of antibody expression were higher in the arthritis subset than in the non-arthritis subset; however, the difference was not statistically significant. This might result from the small number of patients with positive anti-CCP.
Radiographic evaluation of patients with chronic arthritis showed erosive arthritis in only one patient. This patient was the only case with positive anti-CCP among all chronic arthritis cases. The current study did not demonstrate any significant association between anti-CCP positivity and the development of erosive arthritis in the SLE population. This result was in contrast with those of a number of previous studies which have indicated a meaningful association between anti-CCP and erosive arthritis in SLE patients [13, 29] . This lack of association must be cautiously interpreted. The limited number of enrolled patients, the small number of cases with chronic arthritis, and specifically the single case of erosive arthritis may have partially affected the results. Qing et al. have proposed the role of ethnic and geographical variance in the expression of anti-CCP antibodies in SLE patients [21] . Similarly, ethnic and geographical variance may have influenced the results of the current study.
A significant association between serum RF levels and anti-CCP positivity was observed in SLE patients. This finding was similar to previously-described findings in patients with rheumatoid arthritis [10, 11, Anti-CCP in lupus 100 Rheum. Res., Vol. 2, No. 3, Jul. 2017 12, 13, [21] [22] [23] . In contrast, another study of SLE, rhupus, and RA has negated the significant association between anti-CCP levels and erosive or non-erosive arthropathy [27] .
Overall, erosive arthritis was confirmed in only one patient of the current study population. Larger studies on SLE patients are warranted to show a possible correlation between anti-CCP and erosive arthritis.
The current study had a number of limitations, namely, the small sample size and the lack of therapeutic information on arthritis.
Conclusion ___________________________
This study did not show any association of anti-CCP with erosion in SLE patients with arthritis. Future longitudinal studies are needed to further investigate the correlation between erosive arthritis and anti-CCP positivity in SLE.
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